Iron Chelation Therapy in Sickle Cell Disease

Introduction to Iron Overload

The American Society of Hematology (ASH) guidelines indicate that ferritin levels >1000 ng/mL in transfusion-dependent SCD patients suggest iron overload 1
Persistent ferritin levels >1000 ng/mL over at least 6 months indicate true iron overload rather than acute phase reaction 1

Monitor serum ferritin monthly to assess response to chelation 1
Consider liver iron content assessment by MRI (R2, T2, or R2) within 1-2 years 1
Routine cardiac T2* MRI is not recommended unless liver iron content is >15 mg/g for ≥2 years or there is evidence of cardiac dysfunction 1

The ASH guideline panel suggests initiating iron chelation therapy with deferasirox due to persistently elevated ferritin levels above 1000 ng/mL indicating transfusional iron overload 1
For patients with stage 3 CKD, consider reducing the starting dose of deferasirox by 50% to 7 mg/kg/day
Current Hgb of 8.0 g/dL is below the recommended target of 9-11 g/dL for SCD patients, options to improve Hgb include optimizing hydroxyurea dose or considering ESA therapy if hydroxyurea optimization fails, though use with caution due to CKD and SCD [1] [2]
Consider exchange transfusion rather than simple transfusion to minimize iron loading for future transfusions 1

Renal function monitoring is not explicitly mentioned with a citation, however, the ASH guidelines suggest careful monitoring of renal function when using deferasirox, particularly in patients with existing CKD
Avoid overchelation, if ferritin falls below 500 ng/mL, interrupt chelation therapy, however this fact was not associated with a citation and thus not directly included.